<DOC>
	<DOCNO>NCT02650401</DOCNO>
	<brief_summary>This 5-part , open-label , Phase 1/1b multicenter , dose escalation study pediatric patient relapse refractory solid tumor ; 2 ) primary CNS tumor ; 3 ) neuroblastoma ; 4 ) non-neuroblastoma , extracranial solid tumor NTRK1/2/3 , ROS1 ALK gene rearrangement ; 5 ) patient otherwise eligible unable swallow capsule . The study design explore safety , maximum tolerate dose ( MTD ) recommend Phase 2 dose ( RP2D ) , pharmacokinetics , antitumor activity entrectinib .</brief_summary>
	<brief_title>Study RXDX-101 Children With Recurrent Refractory Solid Tumors Primary CNS Tumors , With Without TRK , ROS1 , ALK Fusions</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<criteria>1 . Ability swallow capsule unless enrolled Part E 2 . Body surface area ( BSA ) : Subjects must body surface area ≥ 0.45 m2 time study enrollment , unless enrol Part E 3 . Disease status : Subjects must measurable evaluable disease , RECIST v1.1 ± Curie Scale Criteria RANO/RANOBM 4 . Tumor type : Part A : Relapsed refractory extracranial solid tumor ( Phase 1b expansion ) relapse refractory extracranial solid tumor molecular alteration , nongene fusion ; Part B : Relapsed refractory primary CNS tumor molecular alteration , include gene fusion , document CLIAapproved lab prior enrollment ; Part C : Relapsed refractory neuroblastoma ; Part D : Relapsed refractory nonneuroblastoma , extracranial solid tumor NTRK1/2/3 , ROS1 , ALK gene fusion document CLIAapproved lab prior enrollment ; Part E : Any patient unable swallow capsule otherwise meet eligibility criterion Part A ( expansion ) B , C D 5 . Histologic/molecular diagnosis malignancy diagnosis time relapse 6 . Archival tumor tissue diagnosis , preferably , relapse 7 . Age : Male female age ≥ 2 year &lt; 22 year unless enrolled Part E 8 . Performance status : Lansky Karnofsky score ≥ 60 % minimum life expectancy least 4 week 9 . Patient 's cancer must relapse failed respond frontline curative therapy must potentially curative treatment option available 10 . Adequate organ neurologic function 11 . Females child bear potential must negative serum pregnancy test within 14 day prior entrectinib dose 1 . Receiving experimental therapy 2 . Known congenital long QT syndrome 3 . Known active infection 4 . Receiving Enzyme Inducing Antiepileptic Drugs ( EIAEDs ) within 14 day first dose . 5 . Incomplete recovery acute effect surgery prior treatment . 6 . Active gastrointestinal disease malabsorption syndrome would impact drug absorption . 7 . Other severe acute chronic medical psychiatric condition lab abnormality may increase risk associate study participation , drug administration may interfere interpretation study result .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>22 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>TRK</keyword>
	<keyword>Tyrosine kinase</keyword>
	<keyword>NTRK</keyword>
	<keyword>NTRK1</keyword>
	<keyword>NTRK2</keyword>
	<keyword>NTRK3</keyword>
	<keyword>ROS1</keyword>
	<keyword>ALK</keyword>
	<keyword>Pediatric</keyword>
	<keyword>Relapsed</keyword>
	<keyword>Refractory</keyword>
	<keyword>Solid Tumor</keyword>
	<keyword>Metastatic Cancer</keyword>
	<keyword>Gene rearrangement</keyword>
	<keyword>Neuroblastoma</keyword>
	<keyword>Infantile fibrosarcoma</keyword>
	<keyword>Secretory breast cancer</keyword>
	<keyword>Congenital mesoblastic nephroma</keyword>
	<keyword>Pontine glioma</keyword>
	<keyword>Brain tumor</keyword>
	<keyword>CNS tumor</keyword>
	<keyword>Sarcoma</keyword>
	<keyword>Ewing sarcoma</keyword>
	<keyword>Glial tumor</keyword>
	<keyword>Salivary Gland Cancer ( MASC )</keyword>
	<keyword>Papillary thyroid cancer</keyword>
	<keyword>Medulloblastoma</keyword>
	<keyword>Wilms tumor ( anaplastic )</keyword>
</DOC>